Back

Recombinant chimeric Horsepox Virus (TNX-801) is attenuated relative to Vaccinia Virus Strains in Human Primary Cell Lines and in Immunocompromised Mice

Trefry, S.; Raney, C.; Cregger, A.; Martinez, N.; Layton, B.; Enamorado, R.; Gohegan, D.; Moulaei, T.; Ziolkowska, N.; Geobel, S.; Lederman, S.; Bavari, S.; Nasar, F.

2023-10-26 microbiology
10.1101/2023.10.25.564033 bioRxiv
Show abstract

Recombinant chimeric Horsepox virus (TNX-801) is a preclinical vaccine in development against Monkeypox and smallpox. In this brief report, we investigated the potential phenotypic differences in in vitro and in vivo models between TNX-801 and older VACV-based vaccine strains (VACV-IHD, VACV-Lis, VACV-NYC) used in the eradication of smallpox virus. TNX-801 displayed a small plaque phenotype ([~]1-2 mm) in both BSC-40 and Vero-E6 cells and yielded >10- to 100-fold lower infectious titers than the VACV strains in multiple-step replication kinetics. Growth kinetics in primary human cell lines from two main routes of poxvirus transmission, respiratory and dermal tracts, yielded [~]10- to 119-fold lower infectious titers of TNX-801. Intranasal infection of immunocompromised mice (C56BL/6 Ifnar-/-/Ifngr-/-) with VACV strains at 6.0 and 5.0 log10 PFU produced uniform lethal disease. In contrast, TNX-801 at 8.0 log10 PFU was unable to produce any clinical disease in mice. These data demonstrate that TNX-801 is >10- to 1,000-fold more attenuated than older VACV-based smallpox vaccines in human primary cell lines and immunocompromised mice.

Matching journals

The top 3 journals account for 50% of the predicted probability mass.

50% of probability mass above

"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.